A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Ko, A. H. [1 ]
Dito, E. [1 ]
Schillinger, B. [1 ]
Venook, A. P. [1 ]
Bergsland, E. K. [1 ]
Korn, W. M. [1 ]
Tempero, M. A. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4516
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
    Soares, Heloisa P.
    Bayraktar, Soley
    Blaya, Marcelo
    Lopes, Gilberto
    Merchan, Jaime
    Macintyre, Jessica
    Mayo, Carlos
    Green, Mark R.
    Silva, Orlando
    Levi, Joe
    Walker, Gail
    Rocha-Lima, Caio M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 839 - 845
  • [42] A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
    Heloisa P. Soares
    Soley Bayraktar
    Marcelo Blaya
    Gilberto Lopes
    Jaime Merchan
    Jessica Macintyre
    Carlos Mayo
    Mark R. Green
    Orlando Silva
    Joe Levi
    Gail Walker
    Caio M. Rocha-Lima
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 839 - 845
  • [43] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Takuji Okusaka
    Junji Furuse
    Hiroshi Ishii
    Hideki Ueno
    Masafumi Ikeda
    Kohei Nakachi
    Mina Najima
    Takashi Ogura
    Eiichiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 313 - 319
  • [44] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Morizane, Chigusa
    Okusaka, Takuji
    Furuse, Junji
    Ishii, Hiroshi
    Ueno, Hideki
    Ikeda, Masafumi
    Nakachi, Kohei
    Najima, Mina
    Ogura, Takashi
    Suzuki, Eiichiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 313 - 319
  • [45] Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC)
    Kindler, H. L.
    Gangadhar, T.
    Karrison, T.
    Hochster, H. S.
    Moore, M. J.
    Micetich, K.
    Sun, W.
    Catenacci, D. V.
    Stadler, W. M.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
    Philip Q. Bao
    Ramesh K. Ramanathan
    Alyssa Krasinkas
    Nathan Bahary
    Barry C. Lembersky
    David L. Bartlett
    Steven J. Hughes
    Kenneth K. Lee
    A. James Moser
    Herbert J. Zeh
    Annals of Surgical Oncology, 2011, 18 : 323 - 323
  • [47] A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
    Han, Boram
    Kim, Bum Jun
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Song, Hunho
    Kim, Jong Hyeok
    Park, Choong Kee
    Lee, Jung Woo
    Kim, Min-Jeong
    Zang, Dae Young
    JOURNAL OF CANCER, 2021, 12 (03): : 912 - 917
  • [48] Non-interventional study with Erlotinib/Gemcitabine in patients with metastatic pancreatic cancer
    Oettle, H.
    Tessen, H. W.
    Groschek, M.
    Breuer, F.
    Hoeffkes, H. G.
    Kindler, M.
    Marschner, N.
    Schulze, M.
    Steudel, N.
    Waldschmidt, D.
    Heinemann, V
    ONKOLOGIE, 2013, 36 : 123 - 123
  • [49] A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
    Dickler, Maura N.
    Rugo, Hope S.
    Eberle, CareyA.
    Brog, Edi
    Caravelli, James F.
    Panageas, Katherine S.
    Boyd, Jeff
    Yeh, Benjamim
    Lake, Diana E.
    Dang, Chau T.
    Gilewski, Teresa A.
    Bromberg, Jacqueline F.
    Seidman, Andrew D.
    D'Andrea, Gabriella M.
    Moasser, Mark M.
    Melisko, Michele
    Park, John W.
    Dancey, Janet
    Norton, Larry
    Hudis, Clifford A.
    CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7878 - 7883
  • [50] Gemcitabine (Gem) plus celecoxib in advanced pancreatic carcinoma: A phase II study.
    Marini, G
    Simoncini, E
    Valcamonico, F
    Amoroso, V
    Vassalli, L
    Rangoni, G
    Grisanti, S
    Marpicati, P
    Tiberio, GAM
    Ferrari, VD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 339S - 339S
12345